Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group.
- P. Wen, D. Macdonald, Susan M. Chang
- MedicineJournal of Clinical Oncology
- 10 April 2010
The recognition that contrast enhancement is nonspecific and may not always be a true surrogate of tumor response and the need to account for the nonenhancing component of the tumor mandate that new criteria be developed and validated to permit accurate assessment of the efficacy of novel therapies.
Segmentation of subcomponents within the superior longitudinal fascicle in humans: a quantitative, in vivo, DT-MRI study.
- N. Makris, D. Kennedy, D. Pandya
- BiologyCerebral Cortex
- 1 June 2005
The hypothesis that the four subcomponents observed in non-human primates can also be found in the human brain using in vivo diffusion tensor magnetic resonance imaging (DT-MRI) is evaluated and it is demonstrated that thefour subdivisions could indeed be identified and segmented in humans.
AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.
- T. Batchelor, A. Sorensen, R. Jain
- Medicine, BiologyCancer Cell
- 2007
Mechanisms of migraine aura revealed by functional MRI in human visual cortex
- N. Hadjikhani, M. Sanchez del Rio, M. Moskowitz
- Biology, MedicineProceedings of the National Academy of Sciences…
- 3 April 2001
High-field functional MRI with near-continuous recording during visual aura in three subjects observed blood oxygenation level-dependent signal changes that strongly suggest that an electrophysiological event such as CSD generates the aura in human visual cortex.
Angiogenesis in brain tumours
- R. Jain, E. Tomaso, D. Duda, J. Loeffler, A. Sorensen, T. Batchelor
- Medicine, BiologyNature Reviews Neuroscience
- 1 August 2007
Emerging preclinical and clinical data indicate that anti-VEGF therapies are potentially effective in glioblastoma and can transiently normalize tumour vessels, creating a window of opportunity for optimally combining chemotherapeutics and radiation.
Tracer arrival timing‐insensitive technique for estimating flow in MR perfusion‐weighted imaging using singular value decomposition with a block‐circulant deconvolution matrix
- O. Wu, L. Østergaard, R. Weisskoff, T. Benner, B. Rosen, A. Sorensen
- BiologyMagnetic Resonance in Medicine
- 1 July 2003
OSVD shows promise in providing tracer arrival timing‐insensitive flow estimates and hence a more specific indicator of ischemic injury and a technique that is made time‐shift insensitive by the use of a block‐circulant matrix for deconvolution with (oSVD) and without (cSVD) minimization of oscillation of the derived residue function.
High resolution measurement of cerebral blood flow using intravascular tracer bolus passages. Part II: Experimental comparison and preliminary results
- L. Østergaard, A. Sorensen, K. Kwong, R. Weisskoff, C. Gyldensted, B. Rosen
- MedicineMagnetic Resonance in Medicine
- 1 November 1996
A nonparametric (singular value decomposition (SVD)) deconvolution technique produced the most robust results, giving mean gray:white flow ratio of 2.7 ± 0.5 in six normal volunteers, in excellent agreement with recent PET literature values for age‐matched subjects.
Duvernoy's Atlas of the Human Brain Stem and Cerebellum
- T. Naidich, H. Duvernoy, B. Delman, A. Sorensen, S. Kollias, E. Haacke
- BiologyAmerican Journal of Neuroradiology
- 1 May 2009
This atlas gives radiologists and other professionals who research brain physiology a sophisticated knowledge of anatomy by correlating thin-section brain ...
Diffusion tensor imaging as potential biomarker of white matter injury in diffuse axonal injury.
- T. Huisman, L. Schwamm, A. Sorensen
- MedicineAJNR. American journal of neuroradiology
- 1 March 2004
DTI reveals changes in the white matter that are correlated with both acute GCS and Rankin scores at discharge, suggesting DTI may be a valuable biomarker for the severity of tissue injury and a predictor for outcome.
Biomarkers of response and resistance to antiangiogenic therapy
- R. Jain, D. Duda, A. Sorensen
- Biology, MedicineNature Reviews Clinical Oncology
- 1 June 2009
The current challenges in establishing biomarkers of antiangiogenic therapy are discussed, a number of potential systemic, circulating, tissue and imaging biomarkers have emerged from recently completed phase I–III studies, and all of them need to be validated prospectively.
...
...